Peripheral T-cell lymphoma - historical

Back to Top
The purpose of this page is to provide references to regimens that are obsolete, outdated, or of historical interest only. Is there a regimen missing from this list? See the main PTCL page for current regimens.
Last updated on 2024-07-23:2 regimens on this page
2 variants on this page
 
=Relapsed or refractory=
==Bortezomib & Panobinostat==
===Regimen===
Study 	Dates of enrollment	Evidence	Efficacy
Tan et al. 2015 (SGH651)	2009-2013 	Phase 2 	ORR: 43% (95% CI, 23-63)
====Targeted therapy====
*Bortezomib (Velcade) 1.3 mg/m2 IV once per day on days 1, 4, 8, 11
*Panobinostat (Farydak) 20 mg PO once per day on days 1, 3, 5, 8, 10, 12
21-day cycle for up to 8 cycles
===References===
#Tan D, Phipps C, Hwang WY, Tan SY, Yeap CH, Chan YH, Tay K, Lim ST, Lee YS, Kumar SG, Ng SC, Fadilah S, Kim WS, Goh YT; SGH651 Investigators. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial. Lancet Haematol. 2015 Aug;2(8):e326-33. Epub 2015 Jul 7. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00901147
==Romidepsin monotherapy==
===Regimen===
Study 	Dates of enrollment	Evidence 	Comparator	Comparative Efficacy
Piekarz et al. 2011 (NIH 01-C-0049PTCL)	Not reported 	Phase 2 	 	ORR: 38% (95% CI 24-53)
Coiffier et al. 2012 (GPI-06-0002) 	Not reported 	Phase 2 (RT)	 	ORR: Investigator assessment: 29% Central review: 25%
O'Connor et al. 2019 (LUMIERE) 	2012-2014 	Phase 3 (C) 	Alisertib 	Did not meet co-primary endpoint of PFSMedian PFS: 104 vs 115 days(HR 1.15, 95% CI 0.85-1.56)Did not meet co-primary endpoint of ORRORR: 45% vs 33%(OR 1.67, 95% CI 0.93-3.03)
Note: patients in NIH 01-C-0049 had a median of 3 prior treatments (range 1-11); patients in GPI-06-0002 had a median of 2 prior treatments (range 1-8).
====Targeted therapy====
*Romidepsin (Istodax) 14 mg/m2 IV over 4 hours once per day on days 1, 8, 15
28-day cycle for up to 6 cycles, with optional extension of treatment for patients with stable disease or response
===References===
#NIH 01-C-0049PTCL: Piekarz RL, Frye R, Prince HM, Kirschbaum MH, Zain J, Allen SL, Jaffe ES, Ling A, Turner M, Peer CJ, Figg WD, Steinberg SM, Smith S, Joske D, Lewis I, Hutchins L, Craig M, Fojo AT, Wright JJ, Bates SE. Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma. Blood. 2011 Jun 2;117(22):5827-34. Epub 2011 Feb 25. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT00007345
#GPI-06-0002: Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Borchmann P, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan S, Shustov A, Nichols J, Carroll S, Balser J, Balser B, Horwitz S. Results from a pivotal, open-label, phase II study of romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy. J Clin Oncol. 2012 Feb 20;30(6):631-6. Epub 2012 Jan 23. link to original article dosing details in manuscript have been reviewed by our editors EuroPMC NCT00426764
##Update: Coiffier B, Pro B, Prince HM, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L, Padmanabhan Iyer S, Shustov A, Nielsen T, Nichols J, Wolfson J, Balser B, Horwitz S. Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014 Jan 23;7(1):11. link to original article link to PMC article EuroPMC
##Update: Foss F, Horwitz S, Pro B, Prince HM, Sokol L, Balser B, Wolfson J, Coiffier B. Romidepsin for the treatment of relapsed/refractory peripheral T cell lymphoma: prolonged stable disease provides clinical benefits for patients in the pivotal trial. J Hematol Oncol. 2016 Mar 10;9:22. link to original article link to PMC article EuroPMC
#LUMIERE: Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators. Randomized phase III study of alisertib or investigator's choice (selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma. J Clin Oncol. 2019 Mar 10;37(8):613-623. Epub 2019 Feb 1. link to original article dosing details in manuscript have been reviewed by our editors link to PMC article EuroPMC NCT01482962
Category:Peripheral T-cell lymphoma regimens
Category:Disease-specific pages
Category:T-cell lymphomas
Category:Historical regimens